Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
New science points to 4 distinct types of autism - 2Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- 3The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- 4The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 5ByHeart baby formula from all lots may be contaminated with botulism bacteria, tests show
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- NASA says Maven spacecraft that was orbiting Mars has gone silent
- 'Harmonious' meeting between Merz, Lula despite Belém controversy
- Two Indonesian UN peacekeepers killed in explosion in Lebanon
- Make your choice for a definitive Christmas place to get-away!
- Artemis II astronauts arrive at Florida launch site for first moon trip in 53 years
- WHO suspends medical evacuations from Gaza following death of contractor in 'security incident'
- Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
